Use of home device for early detection of neovascular age-related macular degeneration

Ophthalmic Research

Volumn 48, Issue SUPPL. 1, 2012, Pages 11-15

  Loewenstein, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age related macular degeneration; Choroidal neovascularization; ForeseeHome; Preferential hyperacuity perimetry

Indexed keywords

VASCULOTROPIN INHIBITOR;

ARTICLE; EARLY DIAGNOSIS; HOME DIAGNOSTIC TEST; HUMAN; MEDICARE; METAMORPHOSIS; NEUROIMAGING; PERIMETER; PERIMETRY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TELEMONITORING; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SELF CARE; SENSITIVITY AND SPECIFICITY; TELEMEDICINE; VISION DISORDERS; VISUAL FIELD TESTS; WET MACULAR DEGENERATION;

EID: 84865388964     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000339842     Document Type: Article

References (21)

1. Olsen TW, Feng X, Kasper TJ, et al: Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111: 250-255. (Pubitemid 38183223)
2. Vander JF, Morgan CM, Schatz H: Growth rate of subretinal neovascularization in agerelated macular degeneration. Ophthalmology 1989; 96: 1422-1426.
3. Boyer DS, Antoszyk AN, Awh CC, et al: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252. (Pubitemid 46172497)
4. Kaiser PK, Brown DM, Zhang K, et al: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthamol 2007; 144: 850-857.
5. Rauch R, Weingessel B, Maca SM, et al: Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 2011, E-pub ahead of print.
6. Javitt JC, Zhou Z, Maguire MC, et al: Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003; 110: 1534-1539. (Pubitemid 36962485)
7. Querques G, Querques L, Rafaeli O, et al: Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci 2011; 52: 7012-7018.
8. Lai Y, Grattan J, Shi Y, et al: Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimetry. Retina 2011; 31: 1620-1626.
9. Querques G, Berboucha E, Leveziel N, et al: Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol 2011; 95: 986-991.
10. Loewenstein A, Ferencz JR, Lang Y, et al: Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010; 30: 1058-1064.
11. Stur M, Manor Y: Long-term monitoring of age-related macular degeneration with preferential hyperacuity perimetry. Ophthalmic Surg Lasers Imaging 2010; 41: 598-606.
12. Das R, Shi Y, Silvestri G, et al: Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina 2009; 29: 1013-1018.
13. Isaac DL, Avila MP, Cialdini AP: Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. Arq Bras Oftalmol 2007; 70: 771-776.
14. Loewenstein A, Richard & Hinda Rosenthal Foundation: The significance of early detection of AMD: Richard & Hinda Rosenthal Foundation lecture, The Macula Society 29th annual meeting. Retina 2007; 27: 873-878. (Pubitemid 47485409)
15. Kampmeier J, Zorn MM, Lang GK, et al: Comparison of preferential hyperacuity perimeter test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration (in German). Klin Monbl Augenheilkd 2006; 223: 752-756. (Pubitemid 44681429)
16. Alster Y, Bressler NM, Bressler SB, et al: Preferential hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology 2005; 112: 1758-1765. (Pubitemid 41400012)
17. Goldstein M, Loewenstein A, Barak A, et al: Results of a multicenter clinical trial to evaluate the peripheral hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005; 25: 296-303. (Pubitemid 40517358)
18. Loewenstein A, Malach R, Goldstein M, et al: Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003; 110: 966-970. (Pubitemid 36560498)
19. CATT Research Group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
20. Heier JS: VEGF Trap-Eye Phase III Trial Results. VIEW 1 results. Angiogenesis, Exudation, and Degeneration 2011, Miami, February 2011.
21. Schmidt-Erfurth U: VEGF Trap-Eye Phase III Trial Results. VIEW 2 results. Angiogenesis, Exudation, and Degeneration 2011, Miami, February 2011.